Archives of pathology & laboratory medicine最新文献_第3页

In Reply. 回复中。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-25 DOI: 10.5858/arpa.2024-0067-LE

A. C. Mackinnon, Shuko Harada

引用次数: 0

Clarification of Information in "Navigating Next-Generation Sequencing Laboratory Developed Tests: A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance Tests". 下一代测序实验室开发检验导航 "中的信息澄清：对能力验证、美国食品药品管理局法规和临床实验室性能测试的批判性审视》中的信息。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-25 DOI: 10.5858/arpa.2023-0593-LE

C. M. Lockwood

引用次数: 0

Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology. PIT1和SF1多系垂体神经内分泌肿瘤的临床病理相关性及NKX2.2免疫组化在垂体病理学中的诊断作用

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-23 DOI: 10.5858/arpa.2023-0543-OA

F. M. Doğukan, Hüseyin Karatay, Sabahattin Yüzkan, Şebnem Burhan, Buruç Erkan, Banu Yılmaz-Özgüven

{"title":"Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology.","authors":"F. M. Doğukan, Hüseyin Karatay, Sabahattin Yüzkan, Şebnem Burhan, Buruç Erkan, Banu Yılmaz-Özgüven","doi":"10.5858/arpa.2023-0543-OA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0543-OA","url":null,"abstract":"CONTEXT.—\u0000PIT1 and SF1-multilineage pituitary neuroendocrine tumors (PitNETs) have been defined since the classification of adenohypophysial tumors based on the PIT1, SF1, and TPIT transcription factors.\u0000\u0000\u0000OBJECTIVE.—\u0000To describe the clinicopathologic features of PIT1 and SF1-multilineage PitNETs and to contribute to the pituitary pathology practice by questioning the expression of NKX2.2 in PitNETs.\u0000\u0000\u0000DESIGN.—\u0000We reviewed 345 PitNETs and described the clinicopathologic features of 8 PIT1 and SF1-multilineage tumors. NKX2.2 positivity and staining pattern were compared to those of 45 PitNETs from the control group.\u0000\u0000\u0000RESULTS.—\u0000PIT1 and SF1-multilineage PitNET patients had a mean age of 41.13 (range, 14-58 years) and a mean diameter of 14.0 mm (range, 8-20 mm). The most common clinical presentation was acromegaly (6 of 8), and postoperative remission was achieved in all patients. On histomorphologic examination, a pseudopapillary pattern was seen in 5 of the tumors, either focally or diffusely. In addition to PIT1 and SF1, there was a diffuse staining with growth hormone and a predominantly perinuclear staining with cytokeratin 18. With NKX2.2, all multilineage tumors were positive, of which 5 were diffuse and 3 were focal. In the control group, 8 tumors (8 of 45) were positive, of which only 1 was diffuse and 7 were focal.\u0000\u0000\u0000CONCLUSIONS.—\u0000In conclusion, NKX2.2 is a transcription factor that can be used as an additional tool in pituitary pathology, and PIT1 and SF1-multilineage PitNETs are specific tumors that usually present with acromegaly, show signs of a nonaggressive clinical course, have a pseudopapillary histomorphology, and express NKX2.2.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140669811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Democratizing Artificial Intelligence in Anatomic Pathology. 解剖病理学中的人工智能民主化。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-23 DOI: 10.5858/arpa.2023-0205-OA

Thomas J. Flotte, Stephanie A. Derauf, Rachel K Byrd, T. Kroneman, Debra A Bell, Lucas Stetzik, Seung-Yi Lee, Alireza Samiei, Steven N Hart, Joaquin J Garcia, Gillian Beamer, Thomas Westerling-Bui

{"title":"Democratizing Artificial Intelligence in Anatomic Pathology.","authors":"Thomas J. Flotte, Stephanie A. Derauf, Rachel K Byrd, T. Kroneman, Debra A Bell, Lucas Stetzik, Seung-Yi Lee, Alireza Samiei, Steven N Hart, Joaquin J Garcia, Gillian Beamer, Thomas Westerling-Bui","doi":"10.5858/arpa.2023-0205-OA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0205-OA","url":null,"abstract":"CONTEXT.—\u0000Artificial intelligence is a transforming technology for anatomic pathology. Involvement within the workforce will foster support for algorithm development and implementation.\u0000\u0000\u0000OBJECTIVE.—\u0000To develop a supportive ecosystem that enables pathologists with variable expertise in artificial intelligence to create algorithms in a development environment with seamless transition to a production environment.\u0000\u0000\u0000DESIGN.—\u0000\u0000\u0000\u0000RESULTS.—\u0000The development team considered internal development and vended solutions. Because of the extended timeline and resource requirements for internal development, a decision was made to use a vended solution. Vendor proposals were solicited and reviewed by pathologists, IT, and security groups. A vendor was selected and pipelines for development and production were established. Proposals for development were solicited from the pathology department. Eighty-four investigators were selected for the initial cohort, receiving training and access to dedicated subject matter experts. A total of 30 of 31 projects progressed through the model development process of annotating, training, and validation. Based on these projects, 15 abstracts were submitted to national meetings.\u0000\u0000\u0000CONCLUSIONS.—\u0000Democratizing artificial intelligence by creating an ecosystem to support pathologists with varying levels of expertise can break down entry barriers, reduce overall cost of algorithm development, improve algorithm quality, and enhance the speed of adoption.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140670024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening and Diagnosis of Rare Thalassemia Variants. 罕见地中海贫血变异基因的筛查和诊断。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-23 DOI: 10.5858/arpa.2023-0382-OA

Haishen Tang, Yi Xiong, Jiaqi Tang, Xiaohong Wang, Ya Wang, Liping Huang, Runli Wang, Degang Wang

{"title":"Screening and Diagnosis of Rare Thalassemia Variants.","authors":"Haishen Tang, Yi Xiong, Jiaqi Tang, Xiaohong Wang, Ya Wang, Liping Huang, Runli Wang, Degang Wang","doi":"10.5858/arpa.2023-0382-OA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0382-OA","url":null,"abstract":"CONTEXT.—\u0000Rare thalassemia subtypes are often undiagnosed because conventional testing methods can only identify 23 common types of α- and β-thalassemia.\u0000\u0000\u0000OBJECTIVE.—\u0000To assess a comprehensive approach for the screening and diagnosis of rare thalassemia.\u0000\u0000\u0000DESIGN.—\u0000The study cohort included 72 individuals with suspected rare thalassemia variants. Screening was conducted by next-generation sequencing (NGS) combined with third-generation sequencing (TGS) and chromosomal microarray analysis (CMA)/copy number variation sequencing.\u0000\u0000\u0000RESULTS.—\u0000Of the 72 individuals with suspected rare thalassemia, 49 had rare α- or β-gene variants. NGS combined with gap polymerase chain reaction detected a total of 42 cases, resulting in a positive detection rate of 58.3%. Additionally, 4 α-globin genetic deletions were identified by TGS, which increased the variant detection rate by 5.6%. Two samples with a microdeletion of chromosome 16 or 11 were detected by CMA, which increased the detection rate by 2.8%. For one sample, reanalysis of the NGS and TGS data confirmed the presence of the β41-42/βN and βN/βN mosaic. The HBB:c.315 + 2delT mutation was initially reported in Guangdong Province, China. Two HBB gene mutations (HBB:c.315 + 5G>C and HBB:c.295G>A) and 4 rare HBA gene deletions (-11.1, -α27.6, -α2.4, and -α21.9) were initially identified in the Zhonshan region. The hematologic phenotypes of all rare cases in this study were clarified.\u0000\u0000\u0000CONCLUSIONS.—\u0000Rare thalassemia variants are more common than previously thought. Despite advancements in TGS, there is still no foolproof method for detection of all types of thalassemia. Thus, a comprehensive approach is necessary for accurate screening and diagnosis of rare thalassemia variants.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140671844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma: A Study of 21 Institutions. 浸润性乳腺癌中雌激素受体、孕激素受体和人表皮生长因子受体 2 的表达率：21 家机构的研究。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-18 DOI: 10.5858/arpa.2022-0384-CP

Daniel D Mais, Alia N Nazarullah, Anthony J Guidi, Suzanne Dintzis, Barbara J Blond, Thomas A Long, Suzanne N Coulter, Richard W Brown

{"title":"Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma: A Study of 21 Institutions.","authors":"Daniel D Mais, Alia N Nazarullah, Anthony J Guidi, Suzanne Dintzis, Barbara J Blond, Thomas A Long, Suzanne N Coulter, Richard W Brown","doi":"10.5858/arpa.2022-0384-CP","DOIUrl":"https://doi.org/10.5858/arpa.2022-0384-CP","url":null,"abstract":"CONTEXT.—\u0000Laboratories performing predictive marker testing for breast carcinoma are encouraged to compare patient results to published benchmarks.\u0000\u0000\u0000OBJECTIVE.—\u0000To collect expression rates for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) in invasive breast carcinoma from multiple laboratories.\u0000\u0000\u0000DESIGN.—\u0000Participants submitted data from up to 50 primary cases during the study period. Participants reported ER, PgR, and HER2 results in addition to demographic and histologic information. Participants also provided annual institution-level expression rates.\u0000\u0000\u0000RESULTS.—\u0000A total of 21 institutions submitted data for 687 cases. Aggregate positivity rates for ER and PgR were 85.6% and 75.1%, respectively. Receptor positivity rates were higher in well-differentiated (grade 1) tumors (ER, 97.4%; PgR, 88.0%) compared with moderately differentiated (grade 2) tumors (ER, 92.4%; PgR, 84.0%) and poorly differentiated (grade 3) tumors (ER, 61.8%; PgR, 48.0%). Expression rates were higher in postmenopausal women (ER, 87.2%) than premenopausal women (ER, 79.6%) and higher in lobular carcinomas (ER, 98.7%; PgR, 85.3%) than ductal carcinomas (ER, 84.1%; PgR, 74.5%). The aggregate HER2 positivity (score 3+) rate was 9.0%. The aggregate HER2 equivocal (score 2+) rate was 14.5%. Of 81 equivocal (score 2+) cases, 70 (86.4%) were nonamplified.\u0000\u0000\u0000CONCLUSIONS.—\u0000The data from this study provide multi-institutional benchmark data to assist laboratories performing periodic comparisons as part of a quality management program. Overall expression rates were generally similar to those of other published reports, with the exception of the ER-negative and HER2-positive rates, both of which were somewhat lower.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140686830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients. 小体积循环肿瘤细胞的存在预示着非小细胞肺癌患者的预后较差。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-18 DOI: 10.5858/arpa.2023-0455-OA

Qianqian Sun, Weiqing Li, Donghua Yang, P. Lin, Lina Zhang, H. Guo

{"title":"The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients.","authors":"Qianqian Sun, Weiqing Li, Donghua Yang, P. Lin, Lina Zhang, H. Guo","doi":"10.5858/arpa.2023-0455-OA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0455-OA","url":null,"abstract":"CONTEXT.—\u0000Most patients with non-small cell lung cancers (NSCLC) are diagnosed at advanced stages. The 5-year survival rate of patients with advanced lung cancer is less than 20%, which makes lung cancer the leading cause of cancer-related deaths worldwide.\u0000\u0000\u0000OBJECTIVE.—\u0000To identify indicators that can predict the prognosis of lung cancer patients.\u0000\u0000\u0000DESIGN.—\u0000To determine the correlation between circulating tumor cells (CTCs), circulating tumor-derived endothelial cells (CTECs), and their subtypes and the prognosis of patients with NSCLC, 80 patients with lung cancer were recruited and 48 patients who met the enrollment criteria were selected in this study. Peripheral blood was collected from the enrolled patients before any treatment and analyzed by the subtraction enrichment and immunostaining-fluorescence in situ hybridization technique to determine the correlation between CTCs and CTECs and lung cancer disease progression and to identify prognostic indicators.\u0000\u0000\u0000RESULTS.—\u0000In all patients, the positive rate of CTCs was 100% and the positive rate of CTECs was 81.3%. The CTEC positivity rate was higher in late-stage patients than in early-stage patients (P = .03). Patients with advanced or lymph node metastases had a higher rate of small-size CTC positivity than those with early or no lymph node metastases. Large-size CTEC positivity was higher in patients with advanced NSCLC than in early-stage patients. Patients with ≥1 small-size CTC had shorter progression-free survival, and it was an independent prognostic factor.\u0000\u0000\u0000CONCLUSIONS.—\u0000Small-size CTCs are a reliable prognostic indicator and a probable predictor of the severity of disease in NSCLC patients.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140689739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ten Years of Pathology on Twitter (X): Landscape and Evolution of Pathology on Twitter From 2012 to 2023. 推特上的病理学十年（X）：2012 年至 2023 年推特上病理学的格局与演变。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-11 DOI: 10.5858/arpa.2023-0447-OA

Roland Tian, Eric Wang, Priyadharshini Sivasubramaniam, S. U. Baskota, Anurag Sharma, Matthew J Cecchini

{"title":"Ten Years of Pathology on Twitter (X): Landscape and Evolution of Pathology on Twitter From 2012 to 2023.","authors":"Roland Tian, Eric Wang, Priyadharshini Sivasubramaniam, S. U. Baskota, Anurag Sharma, Matthew J Cecchini","doi":"10.5858/arpa.2023-0447-OA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0447-OA","url":null,"abstract":"CONTEXT.—\u0000Social media is a powerful tool in pathology education and professional networking that connects pathologists and pathology trainees from around the world. Twitter (X) appears to be the most popular social media platform pathologists use to share pathology-related content and connect with other pathologists. Although there has been some published research on pathology-related activity on Twitter during short time frames, to date there has not been published research examining pathology-related Twitter activity in totality from its earliest days of activity to recently.\u0000\u0000\u0000OBJECTIVE.—\u0000To comprehensively evaluate the use of pathology on Twitter (X) during the last 10 years.\u0000\u0000\u0000DESIGN.—\u0000Pathology-related tweets were systematically scraped from Twitter from January 2012 to January 2023 using pathology hashtags as a surrogate measure for all pathology content on Twitter. COVID-related tweets were approximated by tweets containing the term \"COVID.\"\u0000\u0000\u0000RESULTS.—\u0000There were 591 812 unique pathology-related tweets identified during the time period, with #pathology being the most common hashtag used and #PathTwitter becoming more popular since 2020. There has been positive annual growth of pathology Twitter, with peaks in use during major pathology conferences. During the initial phases of the COVID-19 pandemic a sustained increase in pathology tweets was observed.\u0000\u0000\u0000CONCLUSIONS.—\u0000Pathology Twitter has grown during the last 10 years and has become increasingly popular for pathology education and networking. With the changing landscape of social media platforms this study provides an understanding of how pathology medical education and professional networking uses of social media are used and evolve over time.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Interplay Between Human Leukocyte Antigen Antibody Profile and COVID-19 Vaccination in Waitlisted Renal Transplant Patients. 肾移植候选患者的人类白细胞抗原抗体谱与 COVID-19 疫苗接种之间的相互作用

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-11 DOI: 10.5858/arpa.2023-0370-OA

Yayuan Zhao, Pramath Kakodkar, Henry Pan, Richard Zhu, Khalid Musa, Abubaker Hassan, A. Shoker, D. Webster, Twyla Pearce, Pouneh Dokouhaki, Fang Wu, Ahmed Mostafa

{"title":"The Interplay Between Human Leukocyte Antigen Antibody Profile and COVID-19 Vaccination in Waitlisted Renal Transplant Patients.","authors":"Yayuan Zhao, Pramath Kakodkar, Henry Pan, Richard Zhu, Khalid Musa, Abubaker Hassan, A. Shoker, D. Webster, Twyla Pearce, Pouneh Dokouhaki, Fang Wu, Ahmed Mostafa","doi":"10.5858/arpa.2023-0370-OA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0370-OA","url":null,"abstract":"CONTEXT.—\u0000Mass COVID-19 vaccination is mandated in vulnerable populations in our renal transplant waitlist cohort. However, the anti-human leukocyte antigen (anti-HLA) profile after COVID-19 vaccination is controversial, and the side effects are yet to be discerned.\u0000\u0000\u0000OBJECTIVE.—\u0000To evaluate the status of HLA antibodies in waitlist renal transplant patients before and 3 weeks after each vaccination and if comorbidities are associated with the HLA antibody profile.\u0000\u0000\u0000DESIGN.—\u0000A total of 59 waitlisted kidney transplant patients were included in this study. The anti-HLA antibodies were analyzed before and 6 months after their last COVID-19 vaccination. The mean fluorescence intensity change in the anti-HLA antibody levels was used to classify patients into 3 groups: high inducers, low inducers, and noninducers.\u0000\u0000\u0000RESULTS.—\u0000There were significant HLA antibody profile changes after COVID-19 vaccination, showing 21 antibodies generated against HLA class I antigens and 7 against HLA class II antigens to their baseline. Compared with the noninducers, the high and low inducers showed a higher prevalence of COVID-19 infection, COVID-19 vaccine type, and background hypertension history.\u0000\u0000\u0000CONCLUSIONS.—\u0000Our data suggest that COVID-19 vaccination propagates anti-HLA class I and II antibodies for waitlisted renal transplant patients. The clinical significance of these antibodies needs further study. Furthermore, comorbidities, such as history of COVID-19 infection and hypertension, supplemented this effect. Anti-HLA antibody monitoring may be warranted in vaccinated, waitlisted renal transplant patients with COVID-19 vaccinations, and a history of COVID-19 infection or hypertension.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140714581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guidelines for Pathologic Diagnosis of Mesothelioma. 间皮瘤病理诊断指南》。

IF 4.6 3区医学

Archives of pathology & laboratory medicine Pub Date : 2024-04-08 DOI: 10.5858/arpa.2023-0304-RA

A. N. Husain, David B. Chapel, R. Attanoos, M. Beasley, Luka Brcic, K. Butnor, L. Chirieac, Andrew Churg, S. Dacic, Francoise Galateau-Salle, Kenzo Hiroshima, Yin P Hung, Sonja Klebe, Thomas Krausz, A. Khoor, Leslie Litzky, A. Marchevsky, Kazuki Nabeshima, Andrew G. Nicholson, E. Pavlisko, Anja C Roden, Victor L Roggli, Jennifer L Sauter, Jefree J. Schulte, Michael Sheaff, William D. Travis, Ming-Sound Tsao, A. Walts, Thomas V. Colby

{"title":"Guidelines for Pathologic Diagnosis of Mesothelioma.","authors":"A. N. Husain, David B. Chapel, R. Attanoos, M. Beasley, Luka Brcic, K. Butnor, L. Chirieac, Andrew Churg, S. Dacic, Francoise Galateau-Salle, Kenzo Hiroshima, Yin P Hung, Sonja Klebe, Thomas Krausz, A. Khoor, Leslie Litzky, A. Marchevsky, Kazuki Nabeshima, Andrew G. Nicholson, E. Pavlisko, Anja C Roden, Victor L Roggli, Jennifer L Sauter, Jefree J. Schulte, Michael Sheaff, William D. Travis, Ming-Sound Tsao, A. Walts, Thomas V. Colby","doi":"10.5858/arpa.2023-0304-RA","DOIUrl":"https://doi.org/10.5858/arpa.2023-0304-RA","url":null,"abstract":"CONTEXT.—\u0000Mesothelioma is an uncommon tumor that can be difficult to diagnose.\u0000\u0000\u0000OBJECTIVE.—\u0000To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma.\u0000\u0000\u0000DATA SOURCES.—\u0000Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks.\u0000\u0000\u0000CONCLUSIONS.—\u0000There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions.","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140727896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0